ABL, Evivar Strike Cross-license, Marketing Pact | GenomeWeb
Home » ABL, Evivar Strike Cross-license, Marketing Pact

ABL, Evivar Strike Cross-license, Marketing Pact

Sep 29, 2009

NEW YORK (GenomeWeb News) – Advanced Biological Laboratories has reached cross-license and strategic alliance agreements with Luxembourg-based Evivar, Melbourne, Australia-based ABL said today.

The companies have agreed to develop and commercialize their products, including ABL's TherapyEdge and Evivar's SeqHepB system, for use in management and treatment of HIV and Hepatitis B.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Oct 26, 2015

European Trial of Beckman Coulter DxN Veris Shows Workflow Improvements for MDx Testing

Premium
Oct 19, 2015

Roche Gets FDA Approval for Cobas MDx Systems; HBV, HCV Viral Load Tests

Feb 10, 2016

Duke, Emory License CRISPR Tech to Cocrystal Pharma for Virus-Targeting Therapies

May 18, 2016

HIV Screening With Molecular Test Reduces Incidence, Study Finds

Premium
Sep 08, 2016

Hologic Readying Add-On Module, Respiratory Viral Panels for Panther MDx System

Premium
Feb 24, 2016

Hologic Hepatitis C Viral Load Test Fares Well in German Validation

Premium

The Scan

This Week in Science

In Science this week: global genetic diversity map, and more.

To Follow Up On

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

Look into the (Possible) Future

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Urged to Amend

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

What's Popular?

In Clinical & Translational

  1. US Supreme Court Strikes Down Gene Patents but Allows Patenting of Synthetic DNA

  2. Importance of Fetal Fraction DNA in Noninvasive Prenatal Testing

    Premium

  3. DNAnexus to Provide Informatics Infrastructure for ORIEN Initiative

  4. 23andMe Adds BRCA Breast/Ovarian Cancer Testing to Service

    Premium

  5. Startup Diassess Wins New NIH Grant to Develop POC Nucleic Acid Test for Chlamydia

    Premium

Sponsorships

Privacy Policy.  Copyright © 2016 Genomeweb LLC.  All Rights Reserved.